A Study of a Single Dose of ALXN1210 in Healthy Participants
Status:
Completed
Trial end date:
2015-03-13
Target enrollment:
Participant gender:
Summary
This study evaluated the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics
(PD) of a single dose of ALXN1210 in healthy participants, as assessed by electrocardiograms,
physical examination, vital signs, laboratory analysis, and assessment of adverse events
(AEs).